

Chapter 214

Principles of Topical Therapy

Aieska De Souza & Bruce E. Strober

REFERENCES

1. Franz TJ: Kinetics of cutaneous drug penetration. *Int J Dermatol* **22**:499, 1983 [PMID: 6358066]
2. Feldman RJ, Maibach HI: Regional variation in percutaneous penetration of ¹⁴C cortisol in man. *J Invest Dermatol* **48**:181, 1967
3. El Maghraby GM, Barry BW, Williams AC: Liposomes and skin: From drug delivery to model membranes. *Eur J Pharm Sci* **34**:203-22, 2008
4. Trommer H, Neubert RH: Overcoming the stratum corneum: The modulation of skin penetration. *Skin Pharmacol Physiol* **19**:106-121, 2006
5. Tadicherla S et al: Topical corticosteroids in dermatology. *J Drugs Dermatol* **8**:1093-1105, 2009
6. Ryan TJ (ed): *Beyond Occlusion: Dermatology Proceedings*. No. 137 of International Congress Symposium Series. London/New York, Royal Society of Medicine Series, 1988
7. Eaglstein WH, Farzad A, Capland L: Topical corticosteroid therapy: Efficacy of frequent application. *Arch Dermatol* **110**:955, 1974 [PMID: 4441115]
8. Zaghoul SS, Goodfield MJ: Objective assessment of compliance with psoriasis treatment. *Arch Dermatol* **140**:408, 2004 [PMID: 15096368]
9. Carroll CL et al: Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. *J Am Acad Dermatol* **51**:212, 2004 [PMID: 15280839]
10. Kulkarni AS et al: Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. *J Drugs Dermatol* **3**:661, 2004 [PMID: 15624749]
11. Feldman SR: Tachyphylaxis to topical corticosteroids: The more you use them, the less they work? *Clin Dermatol* **24**:229-230, 2006
12. Ricciatti-Sibbald D, Sibbald RG: Dermatologic vehicles. *Clin Dermatol* **7**:11, 1989 [PMID: 2680013]
13. McCarron PA et al: Stability of 5-aminolevulinic acid in novel non-aqueous gel and patch-type systems intended for topical application. *J Pharm Sci* **94**:1756, 2005 [PMID: 15986458]
14. Huang X et al: A novel foam vehicle for delivery of topical corticosteroids. *J Am Acad Dermatol* **53**:S26-S38, 2005
15. Franz TJ, Parsell DA, Halualani RM: Betamethasone valerate foam 0.12 percent: A novel vehicle with enhanced delivery and efficacy. *Int J Dermatol* **38**:628, 1999 [PMID: 10487457]
16. Choi MJ, Maibach HI: Liposomes and niosomes as topical drug delivery systems. *Skin Pharmacol Physiol* **18**:209-219, 2005
17. Karimipour DJ, Karimipour G, Orringer JS: Microdermabrasion: An evidence-based review. *Plast Reconstr Surg* **125**:372-377, 2010
18. Zesch A: Short and long-term risks of topical drugs. *Br J Dermatol* **115**:63, 1986 [PMID: 2427105]
19. Farage MA, Katsarou A, Maibach HI: Sensory, clinical and physiological factors in sensitive skin: A review. *Contact Dermatitis* **55**:1-14, 2006
20. Kligman AM et al: Experimental studies on the nature of sensitive skin. *Skin Res Technol* **12**:217-222, 2006
21. Remitz A, Reitamo S: Long-term safety of tacrolimus ointment in atopic dermatitis. *Expert Opin Drug Saf* **8**:501-506, 2009
22. Kim Y: Management with topical nitrogen mustard in mycosis fungoides. *Dermatol Ther* **16**:288, 2003 [PMID: 14686971]
23. Bashir SJ, Maibach HI: Topical drug testing. In: *Comprehensive Dermatologic Drug Therapy*, edited by Wolverton SE. Philadelphia, W.B. Saunders Company, 2001, p. 911
24. Thaçi D, Salgo R: Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. *Clin Dermatol* **28**:52-56, 2010

